These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34854542)

  • 21. PIK3CA-related overgrowth spectrum (PROS): new insight in known diseases.
    Iriarte Fuster A; Cerdà Serra P; Riera-Mestre A
    Med Clin (Barc); 2021 Nov; 157(10):483-488. PubMed ID: 34281706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related overgrowth spectrum: A brief report.
    Denorme P; Morren MA; Hollants S; Spaepen M; Suaer K; Zutterman N; Labarque V; Legius E; Brems H
    Pediatr Dermatol; 2018 May; 35(3):e186-e188. PubMed ID: 29493003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PIK3CA vascular overgrowth syndromes: an update.
    Hughes M; Hao M; Luu M
    Curr Opin Pediatr; 2020 Aug; 32(4):539-546. PubMed ID: 32692051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Papillary Intralymphatic Angioendothelioma in a Child With
    Debelenko L; Mansukhani MM; Remotti F
    Pediatr Dev Pathol; 2023; 26(2):166-171. PubMed ID: 36775953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
    Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
    Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic basis for vascular anomalies.
    Kirkorian AY; Grossberg AL; Püttgen KB
    Semin Cutan Med Surg; 2016 Sep; 35(3):128-36. PubMed ID: 27607321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome.
    Keppler-Noreuil KM; Lozier J; Oden N; Taneja A; Burton-Akright J; Sapp JC; Biesecker LG
    Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):571-581. PubMed ID: 31490637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatic PIK3R1 variation as a cause of vascular malformations and overgrowth.
    Cottrell CE; Bender NR; Zimmermann MT; Heusel JW; Corliss M; Evenson MJ; Magrini V; Corsmeier DJ; Avenarius M; Dudley JN; Johnston JJ; Lindhurst MJ; Vigh-Conrad K; Davies OMT; Coughlin CC; Frieden IJ; Tollefson M; Zaenglein AL; Ciliberto H; Tosi LL; Semple RK; Biesecker LG; Drolet BA
    Genet Med; 2021 Oct; 23(10):1882-1888. PubMed ID: 34040190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel features of PIK3CA-Related Overgrowth Spectrum: Lesson from an aborted fetus presenting a de novo constitutional PIK3CA mutation.
    De Graer C; Marangoni M; Romnée S; Delaunoy M; Zaytouni S; D'Haene N; Désir J; Donner C
    Eur J Med Genet; 2020 Apr; 63(4):103775. PubMed ID: 31568861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early diagnosis enabling precision medicine treatment in a young boy with PIK3R1-related overgrowth.
    Schönewolf-Greulich B; Karstensen HG; Hjortshøj TD; Jørgensen FS; Harder KM; Frevert S; Hove H; Diness BR
    Eur J Med Genet; 2022 Oct; 65(10):104590. PubMed ID: 35964931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral sildenafil as a treatment option for lymphatic malformations in PIK3CA-related tissue overgrowth syndromes.
    Horbach SE; Jolink F; van der Horst CM
    Dermatol Ther; 2016 Nov; 29(6):466-469. PubMed ID: 27502552
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Pagliazzi A; Oranges T; Traficante G; Trapani C; Facchini F; Martin A; Semeraro A; Perrone A; Filippeschi C; Giglio S
    Front Pediatr; 2021; 9():732836. PubMed ID: 34568242
    [No Abstract]   [Full Text] [Related]  

  • 33. A PIK3CA mutation in an acquired capillary malformation.
    Rosenthal J; Sibbald C; Jen M; Deardorff MA; Treat J
    Pediatr Dermatol; 2020 Jan; 37(1):246-247. PubMed ID: 31830321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular malformations syndromes: an update.
    Martinez-Lopez A; Salvador-Rodriguez L; Montero-Vilchez T; Molina-Leyva A; Tercedor-Sanchez J; Arias-Santiago S
    Curr Opin Pediatr; 2019 Dec; 31(6):747-753. PubMed ID: 31693582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS).
    Vahidnezhad H; Youssefian L; Uitto J
    Exp Dermatol; 2016 Jan; 25(1):17-9. PubMed ID: 26268729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular diagnosis of somatic overgrowth conditions: A single-center experience.
    Lalonde E; Ebrahimzadeh J; Rafferty K; Richards-Yutz J; Grant R; Toorens E; Marie Rosado J; Schindewolf E; Ganguly T; Kalish JM; Deardorff MA; Ganguly A
    Mol Genet Genomic Med; 2019 Mar; 7(3):e536. PubMed ID: 30761771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
    di Blasio L; Puliafito A; Gagliardi PA; Comunanza V; Somale D; Chiaverina G; Bussolino F; Primo L
    Cell Death Dis; 2018 Jan; 9(2):45. PubMed ID: 29352118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delineation of the phenotypes and genotypes of PIK3CA-related overgrowth spectrum in East asians.
    Chen H; Sun B; Liu H; Gao W; Qiu Y; Hua C; Lin X
    Mol Genet Genomics; 2024 Jul; 299(1):66. PubMed ID: 38980418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Four-month-old with severe PIK3CA-related overgrowth spectrum disorder successfully treated with alpelisb.
    Cossio ML; Rodríguez J; Flores JC; De Barbieri F; Flores Á; Marín J; Florin C; Cuevas F; Gutiérrez M
    Pediatr Dermatol; 2024; 41(4):714-717. PubMed ID: 38444084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Scarring in Patients With PIK3CA-Related Overgrowth Syndromes.
    Steiner JE; Cottrell CE; Streicher JL; Jensen JN; King DM; Burrows PE; Siegel DH; Tollefson MM; Drolet BA; Püttgen KB
    JAMA Dermatol; 2018 Apr; 154(4):452-455. PubMed ID: 29516089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.